- Home
- ZYBT vs DHF Comparison
ZYBT vs DHF Comparison
Compare ZYBT & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYBT
- DHF
- Stock Information
- Founded
- ZYBT 2004
- DHF 1998
- Country
- ZYBT China
- DHF United States
- Employees
- ZYBT N/A
- DHF N/A
- Industry
- ZYBT
- DHF Finance Companies
- Sector
- ZYBT
- DHF Finance
- Exchange
- ZYBT NYSE
- DHF Nasdaq
- Market Cap
- ZYBT 206.2M
- DHF 183.3M
- IPO Year
- ZYBT 2025
- DHF N/A
- Fundamental
- Price
- ZYBT $4.97
- DHF $2.54
- Analyst Decision
- ZYBT
- DHF
- Analyst Count
- ZYBT 0
- DHF 0
- Target Price
- ZYBT N/A
- DHF N/A
- AVG Volume (30 Days)
- ZYBT 386.8K
- DHF 451.1K
- Earning Date
- ZYBT 01-01-0001
- DHF 01-01-0001
- Dividend Yield
- ZYBT N/A
- DHF 7.65%
- EPS Growth
- ZYBT N/A
- DHF N/A
- EPS
- ZYBT 0.06
- DHF N/A
- Revenue
- ZYBT $26,111,272.00
- DHF N/A
- Revenue This Year
- ZYBT N/A
- DHF N/A
- Revenue Next Year
- ZYBT N/A
- DHF N/A
- P/E Ratio
- ZYBT $87.02
- DHF N/A
- Revenue Growth
- ZYBT N/A
- DHF N/A
- 52 Week Low
- ZYBT $3.70
- DHF $2.06
- 52 Week High
- ZYBT $10.00
- DHF $2.39
- Technical
- Relative Strength Index (RSI)
- ZYBT N/A
- DHF 45.48
- Support Level
- ZYBT N/A
- DHF $2.50
- Resistance Level
- ZYBT N/A
- DHF $2.57
- Average True Range (ATR)
- ZYBT 0.00
- DHF 0.03
- MACD
- ZYBT 0.00
- DHF 0.00
- Stochastic Oscillator
- ZYBT 0.00
- DHF 50.00
About ZYBT ZHENGYE BIOTECHNOLOGY HLDG LTD
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs and is available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.